TLR7 and neoplasm: Effective TLR7/8 agonists targeting the tumor microenvironment (TME) have been successfully delivered using LNPs by targeting the mannose receptor on M206-like macrophages, reprogramming them to an anti-tumor phenotype and boosting NK and T cell killing ability (Figueiredo et al., 2021).